These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9272344)

  • 1. Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy.
    Hewlett EL
    Dev Biol Stand; 1997; 89():143-51. PubMed ID: 9272344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?
    Granoff DM; Rappuoli R
    Dev Biol Stand; 1997; 89():379-89. PubMed ID: 9272376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological responses to infection with B. pertussis.
    Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
    Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of whole-cell pertussis vaccines.
    Plotkin SA
    Dev Biol Stand; 1997; 89():171-4. PubMed ID: 9272348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis.
    Wassilak SG; Anemona A; Giuliano M; Giammanco A
    Dev Biol Stand; 1997; 89():221-8. PubMed ID: 9272354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bordetella parapertussis infections.
    Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A
    Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of acellular pertussis vaccine in young infants.
    Aoyama T; Iwata T; Iwai H; Murase Y; Saito T; Akamatsu T
    J Infect Dis; 1993 Feb; 167(2):483-6. PubMed ID: 8421187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
    Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian preschool children.
    Zarei S; Jeddi-Tehrani M; Akhondi MM; Zeraati H; Kheirkhah T; Ghazanfari M; Shokri F
    Iran J Immunol; 2007 Jun; 4(2):101-9. PubMed ID: 17652850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing antibody responses to acellular pertussis vaccines.
    Trollfors B
    Dev Biol Stand; 1997; 89():279-82. PubMed ID: 9272361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults].
    Abarca K; Valdivieso F; Potin M; Ibáñez I; Vial P
    Rev Med Chil; 2002 May; 130(5):502-10. PubMed ID: 12143270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.